Agenda:
Day One: Wednesday 4 October 2006
08.00
Registration
08.45
BALLROOM
Opening Welcome:
Reinhard Ambros, Executive Director, Novartis Venture Fund
09.05
Keynote Address; Outlook and trends for Biotech companies in Europe
Dr Peter Reinisch, Partner, Global Life Science Ventures
09.25
Panel Discussion:
Global Investment Trends
Chair: Patrick Treuer, Director, Equity Capital Markets, Credit Suisse
Panellists: Joël Besse, Senior Partner, Atlas Venture
Dr Silvano Cominelli, Investment Advisor, HBM Partners
Dr Alexandra Goll, General Partner, TVM Capital
10.15
Coffee Break
10.45-13.15
Small-Cap Listed Company Presentations
10.45
ROOM ZURICH:
Chair: Peter Kalinka,
Accelsior Group 		ROOM BASEL:
Chair: TBA
ROOM BERN:
Chair: Frances Bornstein,
Northbank Communications
10.50
Amarin
Alan Cooke,
Chief Financial Officer		 Speedel
Konrad P Wirz,
Chief Financial Officer 		CeNeS Pharamaceuticals
Simon Kerr,
Commercial Director
11.05
ADVENTRX Pharmaceuticals
Evan M. Levine,
Chief Executive Officer
 Vectura
Dr Christopher Blackwell,
Chief Executive Officer 		NextGen Sciences
Dr James G Heffernan,
Chief Executive Officer
11.20
pSivida
Dr Jill Ogden,
Commerical Director 		ReNeuron
Dr Michael Hunt,
Chief Executive Officer 		MediGene
Dr Peter Heinrich,
Chief Executive Officer
11.35
4SC
Dr Ulrich Dauer,
Chief Executive Officer		 SGX Pharmaceuticals
Todd Meyers,
Chief Financial Officer 		Oridion Systems
Alan Adler,
Chairman & Chief Executive Officer
11.50
Protox Therpautics
Dr Fahar Merchant,
President & CEO 		Phylogica
Dr Stewart Washer,
Chief Executive Officer 		XOMA
J David Boyle III,
Chief Financial Officer, &
Dr Robert H Gundell ,
Vice President Scientific Corporate Development
12.05
Evolutec
Nicholas Badman,
Chief Financial Officer		 BioMS
Tony Hesby,
Vice President Corporate Affairs 		YM Biosciences
David Kennard,
Director European Operations
12.20
Intercell
Gerd Zettmeissl,
Chief Executive Officer		 Gammacan
Patrick Schnegelsberg,
Chief Executive Officer		 Plethora Solutions
Dr Steven Powell,
Chief Executive Officer
12.35
Sinclair Pharma
Dr Michael Flynn,
Chief Executive Officer, &
Jerry Randall,
Chief Financial Officer		 ProMetic Life Sciences
Pierre Laurin,
Chairman, President & CEO 		TopoTarget
Ulla Hlad Buhl,
Communications Coordinator
12.50
BioXell
Dr Franceco Sinigaglia,
Chief Executive Officer		 tbc tbc
13.05
Questions to panellists Questions to panellists Questions to panellists
13.15
Lunch
14.15-16.10
Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies
14.15
ROOM ZURICH:
IMMUNOLOGY/ONCOLOGY WORKSHOP
Chair: Stan Yakatan,
Katan Associates 		ROOM BASEL:
THERAPEUTICS WORKSHOP
Chair: Christoph Schuler,
SWX Swiss Exchange
ROOM BERN:
THERAPEUTICS WORKSHOP
Chair: Dr Kuno Jung,
Global Life Science Ventures
14.20
ESBATech
Dr Dominik Escher,
Chief Executive Officer		 Kuros Biosurgery
Didier Cowling,
President & CEO 		Neurotune
Dr Andreas Schulze,
Chief Executive Officer
14.35
Astex Therapeutics
Martin Buckland,
Chief Business Officer		 Sirtris Pharmaceuticals
Garen Bohlin,
Chief Operating Officer 		Athenagen
John Donovan,
Chief Financial Officer
14.50
Bionor Immuno
Birger Sørensen,
President & CEO 		PolyMedix
Nick Landekic,
President & CEO 		BioRexis
David King,
Chief Executive Officer
15.05
immatics biotechnologies
Joerg Scheidle,
Managing Director & CFO 		Ablynx
Dr Edwin Moses,
Chairman & CEO 		Faust Pharmaceuticals
Thomas Seoh,
Chief Executive Officer
15.20
Santaris Pharma
Dr Keith McCullagh,
President & CEO 		ACE Biosciences
Ingelise Saunders,
Chief Executive Officer		 mondoBIOTECH
Dr Dorian Bevec,
Chief Scientific Officer & Co-Founder
15.45
Cylene Pharmaceuticals
William G Rice,
President & CEO		 Noxxon Pharma
Dr Sven Klussmann,
Chief Executive Officer & CSO 		Ventaira Pharmaceuticals
Leslie Williams,
President & CEO
15.50
Questions to panellists Questions to panellists Questions to panellists
16.00
Coffee Break
16.30
Keynote Presentation: Financing Life Science Companies; Market Trends in Europe
Dr Heinrich Henckel, Chief Executive Officer, SWX Swiss Exchange
16.50
Investor Roundtable
Chair: Stan Yakatan, Chairman, Katan Associates
Panellists: Lionel Carnot, Senior Investment Professional, Bay City Capital
Michèle Ollier, Principal, Index Ventures
Nick Lowcock, Managing Director, Warburg Pincus
17.50
Cocktail Reception
Day Two: Thursday 5 October 2006
08.00
Registration
09.00
Keynote Address:
The relationship between pharma and biotech
Patrick Flochel, Partner, Ernst & Young
9.15
The evolving biotech M&A market:
Current trends and outlook; M&A vs. IPO
Moderator: Lorenza Castellon, Financial Analyst, Equity Development
Panellists: Dr Genghis Lloyd-Harris MD, PhD, Partner, Abingworth Management
Mike Booth, Director, Life Sciences Equity Research, Canaccord Adams
Dr Carole L. Nuechterlein, Corporate Finance, Head, Venture Investments, F. Hoffman-La Roche
Markus Ewert, Global Head of Search & Evaluation, Novartis Pharmaceuticals
10.10
Orthopaedics: Major Trends in the Industry
Moderator: Heinrich Christen, Partner, Industry Leader Medtech, Ernst & Young
Panellists: Christopher Meyer, Head of Business Development and Strategic Planning, Medtronic Europe
Dr Andreas Baenziger, Partner, MedWork
John Ayliffe, Chief Executive Officer, Precimed
Dr Emmanuel de Haller, Senior Brand Manager, Zimmer
11.00
Coffee Break
11.30-13.30
Sector Workshops: Venture Funded Early – Mid Stage Biotech Companies
11.30
ROOM ZURICH:
IMMUNOLOGY/ONCOLOGY WORKSHOP
Chair: Dr Douglas Pretsell,
Northbank Communications		 ROOM BASEL:
THERAPEUTICS WORKSHOP
Chair: Regina Hodits,
Atlas Venture
ROOM BERN:
MIXED WORKSHOP
Chair: Dimitri Dimitriou,
Dyo Delta Biosciences
11.35
Apoxis
Dr Jean-Pierre Rosat,
Chief Executive Officer		 scil technology
Dr Weishui Weiser,
Managing Director 		Agendia
Dr Bernhard Sixt,
Chief Executive Officer & Co-Founder
11.50
Oxford Immunotec
Dr Peter Wrighton-Smith,
Chief Executive Officer
 FIBREX Medical
Dr Eugen Stermetz,
Chief Financial Officer		 Cellectis
Dr André Choulika,
Chief Executive Officer
12.05
Oxxon Therapeutics
John Berriman,
Executive Deputy Chairman 		Cellerix
Eduardo Bravo,
Chief Executive Officer		 TiGenix
Gil Beyen,
Chief Executive Officer
12.20
ProtAffin Biotechologie
Dr Jason Slingsby,
Chief Executive Officer		 NatImmune
Dr Martin Bonde,
Chief Executive Officer		 Virax Holdings
Dr David J Beames,
Chief Executive Officer
12.35
Cerimon Pharmaceuticals
Dr Paul Sekhri,
President & CEO
PolyPhor
Dr Michael Altorfer,
Chief Financial Officer		 Life Cycle Pharma
Flemming Ornskof,
President & CEO
12.50
tbc tbc Biovertis
Erich Felber,
Chief Executive Officer
13.05
Questions to panellists Questions to panellists Questions to panellists
13.15
Lunch and Close of Conference
* to be confrmed

To download a pdf version of this agenda click here.

Back to top